What is Immunic Therapeutics?
Immunic Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing a pipeline of selective oral immunology therapies. The company's focus lies in treating chronic inflammatory and autoimmune diseases, addressing significant unmet medical needs within the immunology space. Its strategic approach involves leveraging novel therapeutic modalities to create differentiated treatments for patients suffering from debilitating conditions. The company's commitment to innovation positions it as a key player in the biopharmaceutical landscape, aiming to transform patient care through advanced scientific research and development.
How much funding has Immunic Therapeutics raised?
Immunic Therapeutics has raised a total of $1.1B across 4 funding rounds:
Share Placement
$60M
Multiple Rounds
$1B
Share Placement (2022): $60M, investors not publicly disclosed
Stock/Share Issuance (2026): $400M led by TCG Crossover, Avidity Partners, OrbiMed, BVF Partners, and Vivo Capital
Stock/Share Issuance (2026): $400M supported by BVF Partners
Private Equity (2026): $200M, investors not publicly disclosed
Key Investors in Immunic Therapeutics
TCG Crossover
TCG Crossover (TCGX) is a science-driven investment firm focused on advancing disruptive medicines. The company aims to invest in breakthrough therapies that have the potential to transform healthcare. Their target clients include innovators in the pharmaceutical and biotechnology sectors. TCGX is committed to supporting the development of extraordinary medical solutions.
Avidity Partners
Avidity Partners, LLC specializes in post confirmation Chapter 11 Trustee services, including liquidation and litigation trusts responsible for claims reconciliation and resolution, distribution of assets to creditors, prosecution of preference and avoidance actions and claims against insiders and third parties. Avidity Partners handles all aspects of §363 and other assets sales, asset management, post-sale transactions and corporate dissolutions. Avidity Partners has distributed over two billion dollars to creditors in the last five years.
OrbiMed
OrbiMed Advisors LLC operates as a specialized investment firm focused on the healthcare sector, with deep expertise spanning multiple therapeutic and commercial domains. The firm manages capital across biopharmaceuticals, medical devices, digital health platforms, diagnostics, and healthcare services, bringing together investment professionals with extensive experience in life sciences and healthcare business development. The firm's investment approach reflects a comprehensive understanding of healthcare innovation cycles and market dynamics.
What's next for Immunic Therapeutics?
The recent major strategic investment of $200M positions Immunic Therapeutics for accelerated growth and pipeline advancement. This capital infusion is expected to fuel the progression of its clinical trials and further research into its selective oral immunology therapies. The company's trajectory suggests a focus on scaling operations and potentially preparing for future commercialization efforts. With a clear strategy and significant backing, Immunic Therapeutics is poised to make notable advancements in the treatment of chronic inflammatory and autoimmune diseases, reinforcing its position in the competitive biopharmaceutical market.
See full Immunic Therapeutics company page
